In the closing act of the Industry Focus Awards, the cast revisits Foolish listener emails before pitching their nominees for most likely to succeed and the infamous participation award.

Notable quotes and M&A take the stage as the next two categories up for grabs. Find out who went home with a prestigious IF Award in hand.

The show must go on! In this episode, the cast doles out their awards for the next two categories: best fact and most valuable player.

Happy holidays, Fools! This year, the Industry Focus cast is rolling out the red carpet for some of their favorite stocks with the first annual Industry Focus Awards ceremony. The first two categories for your consideration: biggest PR blunder and rookie of the year.

We hit the biggest stories of the year — iPhone X, net neutrality, AR/VR, and Verizon buying Yahoo — and talk about how they may impact 2018.

Top Energy and Industrials Headlines From 2017. We look back across various events of the past year in our sector. From arrests of Volkswagen executives to GE’s 40% drop, 2017 has been a big year.

Repeal and replace wasn't the only healthcare story this year! Critical policy changes,  revolutionary new medicines, and M&A also sent healthcare stocks on a wild ride in 2017.

Looking back on a busy year, the cast recaps some of the biggest stories and developments in the sector.

Slack: Where work happens. Find out why at slack.com.

Financials takes a look back at the five biggest news stories of 2017 and what they mean to investors.

We're excited for 2018. Why? We've got tax code changes impacting the books of big tech, plus the next phases of the cable revolution, and the continued rise of e-sports.

Alternative fuels are still a long way from being ubiquitous but some are gaining steam thanks to a few key players. We discuss what constitutes an alternative fuel, why commercial and heavy goods transport is the gateway to alternatives adoption, and stocks investors may want to consider. Today the show was sponsored by Harrys.com/Fool

Celgene and bluebird bio report a stunning success in multiple myeloma, Juno Therapeutics takes it on the chin despite positive data, and Spark Therapeutics suffers in its showdown with BioMarin in hemophilia.

Subscription-box services have grown incredibly popular in the past few years, and Stitch Fix is the latest company based on this business model to go public. With almost $1 billion of revenue in 2017, we dive into this fast-growing company and what investors need to know about its data-centric approach to selling apparel.

To get a limited edition holiday shave set while supplies last, go to Harrys.com/fool.

Industry Focus: Financials takes a deep dive into Goldman Sachs and Morgan Stanley’s business models, valuation, and future growth potential.

These tech unicorns have long been the subject of IPO speculation. But for all that buzz, are any of them actually good businesses to own long-term?

UPS, FedEx, and USPS will deliver an estimated two billion packages during the holiday season. We discuss how they make this happen, their past and current struggles to do so profitably, and what this all means for retailers, consumers, and investors.

The tax bill includes fine print that could make biopharma companies pay more in taxes than expected. Plus, CVS Health cozies up to Aetna and Apple takes aim at heart disease.

Cut costs, streamline operations, and acquire growth. That has been the recipe for success for 3G Capital (and frequent partner Warren Buffett), but as headwinds mount for packaged food and beverages, Kraft Heinz needs to find other avenues for growth. The cast also looks at Etsy and its trajectory under new CEO Josh Silverman.

Financials takes a deep dive into BofI Holding’s business model, competitive advantages, valuation, and potential future growth catalysts.

We take a look at a few tech products on holiday shopping lists -- Nintendo Switch, Fitbit Ionic, and Xbox One S/X -- and talk about what their popularity really means for the companies that make them.

Nebraska Public Service Commission voted 3-2 to approve an alternative route for the Keystone XL pipeline through the state. We discuss potential implications of Keystones operator TransCanada, and what the decision might mean for investors. Ahead of the OPEC meeting in Vienna, we debate the rumors and conjecture around the assembly.

Canopy Growth co-founder Bruce Linton is interviewed about the company’s strategy for medicinal and recreational marijuana in Canada and beyond.

Early numbers are in for the Black Friday weekend with strong growth over last year. That momentum has even extended to brick-and-mortar retailers, which saw only small traffic declines during the busy period. Find out why department stores are feeling confident about the quarter, and what investors should watch as they head into the final month of the year.

Slack: Where work happens. Find out why at slack.com.

Financials sets the record straight on common money myths involving topics ranging from investing in stocks to using credit cards.

You know the market is risky and you shouldn't own just one or two stocks, but you're probably wondering how many stocks you should own. In today's episode, we dig into diversification to help you build a better portfolio.

While AT&T and Time Warner investors prepare themselves for a tough legal battle with the Justice Department to close their merger, competitors are circling the valuable media empire that could be going up for sale at Twenty-First Century Fox.

Financials looks at the two tax reform bills currently making their way through Congress, the differences between them, and the likely winners and losers of tax reform.

Roku's first report as a publicly traded company couldn't have gone better. With a second look at their books, are we more sold on the long-term viability of the streaming company?

Editor's note: In the show, we mistakenly said that 1/3 of Roku's platform revenue comes from licensing. That 1/3 portion of the platform revenue is actually from content distribution, the licensing portion is much smaller.

Thanks to Harry’s for supporting Motley Fool. Harry’s will give you their trial shave set for FREE when you sign up at Harrys.com/FOOL - just pay for shipping!

The U.S is increasingly being powered by cheap natural gas and the deployment of pipeline infrastructure is ensuring this remains the case for years to come. In this show we discuss why the commodity is growing in popularity, the billions of dollars being spent transporting it across the country, and investment opportunities in the industry.

A flurry of news has investors clamoring to add Nektar Therapeutics to their portfolios. Plus, we explain why investors are disappointed by Loxo Oncology’s good news and how a new smart pill could change medicine forever.

Shares of the #2 toy company and casual dining chain are both up double digits thanks to buyout rumors. For Mattel, the potential deal with Hasbro would create a dominant player in the toy industry. Meanwhile, a private equity firm with significant restaurant experience is courting B-Dubs. The team also takes a look at Canada Goose, one of the best-performing IPOs of the year.

Thanks to Harry’s for supporting The Motley Fool. Get your Free Trial Set -- go to Harrys.com/fool.

Financials looks at robo-advisors, the automated substitute for financial advisors that has surged in popularity.

After missing on revenue, earnings, and users, shares of Snap got pummeled following the company's Q3 earnings release. We work through the release, talk about the company's transition to auction-based ad sales, and check in on the Spectacles hardware segment.

Utilities have historically been classified as safe and boring but the industry is changing and there are some potentially exciting opportunities in the often overlooked segment.

The much-maligned company is making progress on its restructuring plan, but it's not out of the woods yet. Plus, why Keryx Pharmaceuticals shares tumbled despite winning an FDA approval that more than doubles its addressable market.

In 2014, regulatory opposition forced Sprint to give up on its plan to acquire T-Mobile. Three years later, the two companies returned to the negotiating table, coming close to finalizing an agreement before the deal fell apart once again. What happened? And what lies ahead for the No. 3 and 4 wireless providers?

Financials looks at the new Federal Reserve chair, rising interest rates in the U.K, and the end of the CFPB class action rule.

Great earnings releases from Microsoft and Amazon highlight one thing in particular -- the cloud business is booming for both tech giants.

2017 hasn’t been kind to GE so far. Three months in we discuss the moves new CEO John Flannery is making to right the business, rumors around the November 13^th meeting, and give our bull and bear cases for the stock.

Beer, wine, and spirits Goliath Constellation is acquiring a 10% stake in marijuana stock Canopy Growth, plus why CVS Health is eyeing Aetna, and how one fast-growing upstart is fighting back at colon cancer.

The Toys “R” Us bankruptcy filing in September sent waves through the industry as toy companies cut shipments to the retailer and adjusted their forecasts ahead of the holiday shopping season. However, the latest earnings results from Mattel and Hasbro paint a picture of two industry leaders with very different outlooks.

Financials looks at statistics about emergency savings, credit cards, retirement saving, stock investing, and homeownership.

AMD and Twitter both beat expectations with their quarterly numbers, so why is the social media company flying while shares of the semiconductor company get pummeled?

FreshBooks.com/FOOL and enter MOTLEY FOOL in the “How Did You Hear About Us?” section

We discuss U.S. manufacturing, policy making, and how technology will unlock efficiencies in the oil and gas industry with Mark Mills. Mark has a long and illustrious career as a policy advisor, fund manager, and physicist.

A scary sell-off in Celgene and Ionis Pharmaceuticals shares may have you thinking "sell", but there are good reasons why you shouldn't let what's spooking other investors shake you out of your stock too.

Up over 70% in the past year, the iconic newspaper has enjoyed a major boost in readership thanks to the current presidential administration. Meanwhile, Blue Apron struggles to build momentum as meal kit rival HelloFresh prepares for its IPO.

Thanks to Freshbooks for supporting the Motley Fool.  Get a 30-day free trial by going to FreshBooks.com/FOOL and enter “MOTLEY FOOL” in the “How Did You Hear About Us?” section.

Financials takes a look at bank earnings, important metrics, and catalysts that could move bank stocks higher.

We wrap up pitch week with discussions of IBM, Netflix, and Mindbody. If you want the whole list of pitch week stocks, email industryfocus@fool.com!

Three Motley Fool contributors pitch General Motors, NV5, and Transocean as stocks investors might want to watch.

Novocure, Precision Medicine, and Celgene are three top healthcare stocks. The team discusses their business models and biggest risks in this edition of “Pitch Week.”

“Pitch Week” continues on Industry Focus as our Foolish contributors share their takes on Under Armour, Dave & Buster’s, and Tractor Supply Co.

Thanks to Harry’s for supporting the Motley Fool. Get your free trial set -- go to Harrys.com/fool.

We kick off "Pitch Week" with a look at payment companies Mastercard and Square, and wrap the show with a breakdown of why Warren Buffett's Berkshire Hathaway has been such a good business to own.

Netflix got a nice bump after announcing price increases to several of its service tiers – what might the increases mean for the company’s top line and what should investors be paying attention to ahead of the company’s earnings report next week?

The U.S. has a huge number of investment opportunities in the well-developed energy industry. We discuss why the U.S. oil and gas sector has developed the way it has, some complexities in investing in overseas energy companies, and a few stocks with foreign flare you might want to consider.

Mylan launches a generic "at-risk" and Flexion's big drug opportunity becomes clearer.

Editor's note: Mylan's drug was mistakenly referred to in the episode as a biosimilar. Copaxone, however, was approved under an NDA, not a BLA, so Mylan's copycat is a generic, not a biosimilar.

We look at the latest quarterly earnings from some of the top performers in the alcohol and restaurant industries.

Slack: Where work happens. Find out why at slack.com.

Financials takes a look at share buybacks, dividends, and other ways of returning capital to shareholders.

Now that we have a sense of Roku's valuation, what do we think of it? That, plus a rundown on all the cool new devices Google showed off earlier this week and their impact on the smartphone, smart home and camera markets. Get $25 off your first purchase at http://bombfell.com/fool

Tesla missed Q3 Model 3 production targets by 83%. We debate how concerned investors should be, some good news from the update, and a potentially exciting development on the horizon.

Thanks to Bombfell for supporting The Motley Fool.  Get $25 off your first purchase at http://bombfell.com/fool

Wondering if you can buy, sit back, and collect money on top dividend stocks Johnson & Johnson, AbbVie, and Pfizer? You've come to the right place! In today's episode, we offer up insight into the risk and reward associated with owning these three dividend darlings. 

We dive into the high-end corner of the retail industry with one of the most famous luxury brands in the world: Tiffany. Its signature blue boxes have delighted people around the world, and new leadership is now looking ahead to the challenges posed by changing consumer tastes, especially among younger shoppers. We also look at the latest acquisitions from Coca-Cola and Wal-Mart.

President Trump is interviewing candidates to replace Janet Yellen atop the Federal Reserve. In this episode of Industry Focus: Financials, we dig into the two types of candidates he's considering for the position, and how that will impact the central bank's policies.

Investors may soon be able to claim a stake in rapper Eminem's music catalog, thanks to a new company Royalty Flow and the JOBS Act. We run through what's been going on in the equity crowdfunding and mini-IPO space, and how these types of investment opportunities are very different than investing in the stocks we normally talk about.

We debate the potential implications of the ITCs recommendation for solar import restrictions, the recent rally in oil prices, and the news that GE is selling its Industrial Solutions business.

Unpacking Axovant Sciences big Alzheimer’s disease disappointment, plus Pfizer accuses Johnson & Johnson of unfairly increasing healthcare costs.

Between its upcoming ESPN and Disney-branded services, the company will give viewers access to 10,000 live sporting events, 500 films, and over 7,000 television episodes. Traditional pay-TV subscriber numbers are on the decline, and CEO Bob Iger sees this streaming transition as his last major priority before retirement.

Data center REITs promise ever-growing dividends from a portfolio of data center assets located all around the world, but growing piles of data don't necessarily lead to extreme rewards for shareholders.

Alarm.com, Impinj, and Paycom aren't household names yet, but these tech-savvy upstarts are transforming billion dollar markets and that could make them savvy stocks to buy.

Thanks to Harry’s for supporting Motley Fool. Get your Free Trial Set – go to Harrys.com/fool

Auto sales have declined 2% this year after sales broke records in 2016, leading many commentators to speculate whether the U.S. has reached peak auto. However, one area of the market – SUV’s, light trucks, and crossovers – continues to demonstrate growth.

Thanks to Harry’s for supporting Motley Fool. Get your Free Trial Set – go to Harrys.com/fool

We rip open the mailbag and answer "what gives with interim clinical trials?", "how can drugmakers use patents to stiff-arm generics?" and "why aren't pharmacies cashing in on baby boomers?"

Chegg is leading its corner of the classroom with a wide variety of student services, including college applications, textbook materials, and online tutoring. Meanwhile, 2U is acting as a pioneer for online education by creating graduate programs with some of the most prestigious universities in the country. Both of the companies are enjoying double-digit annual growth rates and stand to gain as technology takes on an increasing role in classrooms around the world.

The team talks about how the insurance industry works and how health insurance differs substantially from other types of insurance. With information about evaluating supplemental health insurance policies, planning for Medicare at age 65, and managing the transition from work-related coverage to Medicare, this program will tell you what you need in order to make a more informed decision for your financial and health situation

Edge-to-edge display? Check. Wireless charging? Check. Facial recognition components? Check. The iPhone X is gorgeous, but what does its release timing mean for Apple’s financials over the next few quarters? We dig into that and Apple’s other upcoming products.

After years of being dubbed “death traps” for investors the Airlines industry is having something of a renaissance. We discuss which of the big four U.S. national carriers is the better buy for investors today.

A new study concludes it costs $757 million to develop a new cancer drug, but is that the only reason why drugmakers charge sky-high drug prices or are other reasons to blame too?

In a strange twist, the newest retail store from Nordstrom will carry no inventory. Instead, the company hopes a unique menu of services will provide a rich enough experience to connect with shoppers – a trend that is growing quickly in the brick-and-mortar world. The cast also looks at how Starbucks is faring under the new leadership of Kevin Johnson.

It’s not always an easy decision, and in most cases you should do some planning first, but there are times when you’re doing the right thing in quitting your job.  Of course there’s a difference between wanting to quit and needing to quit and some things you should do before giving notice.

The streaming service is planning to go public soon and we have our hands on their filing with the SEC! We run through the company's books, talk about the streaming space, and take a look at the company's long-term prospects.

Energy Secretary Rick Perry announced the Department of Energy is releasing 500,000 barrels of oil from the Strategic Petroleum Reserves. We discuss the impact and importance of the move.

Promo: Big-cap biopharma could come knocking if Juno Therapeutics’ next-generation CAR-T is safer than its competitors, and Medtronic's already investing billions in Mazor Robotics, a maker of surgical robots. Sponsored link: http://www.casper.com/fool Code: fool.

Amazon has already begun to weaponize its Whole Foods stores, and we look at how competing retailers like Kroger and Costco are feeling the pressure. Meanwhile, the major dollar store chains are facing their own challenges from larger retail rivals.

Thanks to Casper for supporting the podcast. Save $50 on a mattress at http://www.casper.com/fool, code “fool”.

IF brings you stories and coverage of different sectors of the stock market every day, but what trends are the hosts most excited about, and what stocks are on their watch lists? We bring everyone into the studio for this bonus episode to answer these questions and introduce the new Thursday host Sarah Priestley.

We toss around some terms week-to-week and don't always do the best job explaining them in-depth. Today, we dust off our college accounting books to talk about the difference between capitalizing and expensing a purchase, what deferred revenue is, and why operating leverage is a beautiful thing.

In the ongoing devastation of Hurricane Harvey headlines are surfacing about the storms impact on US oil and Gas -- on this episode we discuss potential outcomes for the industry, and touch on the recent appointment of a new CEO for GE.
 

The FDA approved the world's first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion. 

Join us for a look at the incredible growth of e-sports and the opportunity it presents to various industry stakeholders, including game publishers, content networks, and the players themselves. We also discuss the recent legal troubles at iRobot.

Two years ago we tossed out a terrible ballpark on the revenue Apple Music might be able to bring in for the tech giant. Today we talk about that mistake and how to set yourself up to make better projections.

Thanks to Harry’s for supporting Industry Focus. Get your free trial set – go to Harrys.com/fool

Everyone makes mistakes, the important thing is to learn from them.

We said what? Let’s face it, sometimes our predictions miss the mark, and with Rite Aid and Opko Health, they missed the mark by a lot. Here’s what we said, why we said it, and what we learned from our mistakes.

We said what?!? That is our theme for Industry Focus this week, and we continue the discussion with missed calls on Wal-Mart’s Jet.com acquisition and the 2,000 stores Amazon was supposed to open in the next several years.

Thanks to Harry’s for supporting the Motley Fool. Get your Free Trial Set -- go to Harrys.com/fool.

Everyone makes mistakes. But not many of us air them publicly. That's the theme of this week's Industry Focus, starting with our prediction in 2015 that concerns about Wells Fargo's cross-selling culture were much ado about nothing.

We run through recent wearables market data from Strategy Analytics, check in on the major players, and talk about the long-term outlook for Fitbit.

A solar eclipse occurs Monday -- what that means for solar producers may surprise you.

With a slate of promising drugs hitting the market and in its development pipeline, Regeneron Pharmaceuticals is becoming one of biotechs most important players.

For several years, Procter & Gamble has been spinning off low-priority brands and cutting costs to streamline its business. But with little to show for those efforts, billionaire Nelson Peltz wants a seat at the table. Meanwhile, a slow summer blockbuster season is taking a major toll on theater operators.

Business development companies are undergoing a sea change as the asset class becomes more institutionalized.

Snap's quarterly update was... uninspiring. On this show, we talk about the updated user counts, ask some questions on engagement metrics, and run through the new financials.

Fracking has been the oil industry buzzword for years, here’s what the process actually means.

Scotts Miracle Gro could be the best marijuana stock to buy, while Illumina could be the best bet to capitalize on DNA-based medicine.

You might not be able to fire the coach or have a say in drafting new players, but there are ways to invest in professional sports.

Here's the differences between the major credit card processors, and how to evaluate them as investments.

We try and decode what's going on with Twitter's DAU/MAU numbers, and run through the figures on another banner quarter for the world's largest company.

Years after the downturn started, oil majors relent and believe $50 oil is the new reality. Are they right?

How Celgene and Gilead Sciences results are fueling their stock prices this quarter, plus Merck’s Keytruda closes the sales gap between it and Bristol-Myers Squibb’s Opdivo.

We break down the latest developments in the consumer-retail sector, including Amazon earnings, the $1.4 billion Jimmy Choo buyout, and the turnaround prospects for Target.

Get $25 off your first purchase at http://bombfell.com/fool.

Before you follow an advisor's advice on these topics, make sure you know the whole story.

New quarterly numbers from Alphabet and Facebook sent the stocks in different directions -- why did the Street love one set of estimate-beating numbers and not the other?

Fossil fuels may be critical today, but that fact is changing at an accelerated rate.

Hunting for new small cap stocks to watch? We've got you covered. In today's show, we discuss how NovoCure, Flexion Therapeutics, and Zogenix want to shake-up healthcare.

Michael Kors scoops up Jimmy Choo to keep pace with Coach, and Lululemon's back after a spring mishap, could its winning days continue? We hit these retail news items and check in on Chipotle's food-borne illness problems ahead of earnings.

For years after the financial crisis, bank earnings fluctuated wildly due to high loan losses, volatile markets, and elevated legal expenses. Fortunately, this trend seems to have come to an end, as the results from the second quarter demonstrate.

Shopify and its founder Tobias Lütke have been Fool favorites for a long time -- on this episode we talk about how, despite the stock's crazy run over the past year, we're still interested in the e-commerce company.

Thanks to Harry’s for supporting Motley Fool. Get your Free Trial Set – go to Harrys.com/fool

OPEC’s production cut compliance continues to drop, is this the end of its attempt to prop up oil prices?

After Puma Biotech's recent success, the search is on for other clinical-stage biotech stocks being run by proven CEOs. Could experience turn Aurinia Pharmaceuticals, Axovant Sciences, and Esperion Therapeutics into winners too?

Thanks to Slack for supporting Motley Fool. Learn more at slack.com.

We field Foolish questions from the world of consumer and retail. First, Levi wants to know about the prospects for apparel retailer Buckle (and its double-digit dividend yield). Meanwhile, Shubhra is curious about Kirkland Signature and why the Costco private label is available on Amazon.com.

Thanks to Harry’s for supporting Industry Focus. Get your Free Trial Set -- go to Harrys.com/fool.

Brian Patrick Eha, author of How Money Got Free, joins Gaby Lapera to discuss cryptocurrencies, tokens, blockchain technology, and what it all means for investors, regulators, and financial systems.

Thanks to Slack for supporting Motley Fool. Learn more at slack.com.

We love covering IPOs, but we can't bring ourselves to buy a stock that's only been publicly traded for a few months. We explain why on the final episode of "never will I ever week."

 We all make investing mistakes, but buying a commodity producer lacking a cost advantage shouldn’t be one of them.

Only 10% of drugs make it across the FDA finish line from phase 1 clinical trials, making acquiring pre-clinical biotech stocks the riskiest game in town.

We continue with our theme for this week, as Asit Sharma explains the major hurdles day traders and speculators face in their pursuit of easy profits.

In this episode of Industry Focus: Financials, we dig into things we'd never do -- or, at least, that we try to avoid. This includes investing advice, as well as pointers about life more generally.

Looking for a beach read or a podcast to pass the time on the family trip? We run through some of our favorite tech books and shows so you can still get your fix during the slow months of summer.

Thanks to Slack for supporting Motley Fool. Learn more at slack.com.

Is being late better than never arriving for America's biggest oil major?

After Walgreens' abandoned plans to buy it lock-stock-and-barrel, Rite Aid shares are crashing. Does this give Amazon.com the moment it's been waiting for to disrupt the prescription drug market?

Thanks to Slack for supporting Motley Fool. Learn more at slack.com.

There's no one, right answer, but getting a job while in school can help teach a lot of important things. Tune in to find out what Motley Fool contributors Dan Kline and Gaby Lapera think you ought to know.

In the past month, Pandora has sold off Ticketfly, announced a large investment stake from Sirius, and had its CEO step down. What should investors make of the shake-up? Plus we check in on Apple Music and Tesla's puzzling streaming music ambitions.

Solar stocks are finaly rallying after a year of malaise, is this the long-rumored revound?

The Congressional Budget Office announces a discouraging outlook for Trumpcare. And Portola Pharmaceuticals’ shares increase more in one day than they cost last November.

After spending several months covering casualties, headwinds, and consolidation in the retail sector, we turn our attention to two companies that have thrived in the era of e-commerce. Ulta Beauty and TJX Companies are growing thanks to their physical store footprints, not in spite of them.

Credit ratings agencies (CRAs) have the power to move markets, and decide the fortunes of publicly-traded companies around the world.

What doesn't MercadoLibre do? Today we talk about the Amazon/eBay/Craigslist/PayPal of Latin America, what's been fueling its impressive growth, and some of the things investors need to keep in mind if they're considering buying in.

Thanks to Thumbtack for supporting Motley Fool (thumbtack.com).

There’s lots of ways to move goods and people in today’s economy, but which option is the most economical?

AbbVie is developing new drugs to sidestep expiring patents on its best-seller, and a new FDA approval could be on deck at Clovis Oncology. Also, how Novartis plans to shake-up a multibillion dollar indication.

he grocery industry is bracing itself for further disruption as e-commerce giant Amazon announced a surprise buyout of Whole Foods Market. Meanwhile, the Nordstrom family is weighing their options for taking the department store private.

Thanks to Thumbtack for supporting the Motley Fool.  Hire local, skilled pros for just about anything at thumbtack.com today.

If you're a recent graduate, congratulations! Here's what you need to know about your money.

Apple is one of the most bet against stocks in the market... kind of. We explain why it's true, but kind of a misleading stat.

GE’s CEO may have just retired, but he left the company perfectly positioned for a green-energy fueled future.

A Supreme Court decision that speeds biosimilar drugs to market makes investing in biosimilar stocks even more enticing.  

Discount supermarket chain Aldi will be investing billions in the U.S. market over the next five years, while its fellow German-based rival Lidl prepares to open its first U.S. locations this week. But the biggest winner from this growing competition will be the U.S. consumer.

The House of Representatives voted last week in favor of the Financial CHOICE Act, which is designed to roll back the enhanced regulatory regime laid out in the Dodd-Frank Act of 2010. On this episode of Industry Focus, we dig into the Financial CHOICE Act and discuss what this means for banks.

The average investor has a wealth of information at their fingertips, they just need to know where to find it. We talk about our favorite free tools and resources, and Michael Douglass explains why he thinks "the numbers obscure the true story."

Railroad stocks have consistently beaten the market – here’s why investors should give them a look today.

Bluebird bio, TG Therapeutics, and Loxo Oncology investors are smiling following bullish presentations for their respective cancer drugs at the annual American Society of Clinical Oncology conference this week.

Sponsored link: http://www.casper.com/fool code fool.

In its last private funding round, Blue Apron reached a valuation of over $2 billion. Now, the company has its sights set on the public market, and we are digging into the IPO filing to break down the financials and business model of meal kit delivery for investors.

Citizens Financial became the biggest bank stock IPO in history when it went public in 2014. Since then, it's orchestrated an impressive turnaround.

Sponsored link: http://www.casper.com/fool code fool.

Last week we showered Activision, Take-Two, and EA with love, but what about pure-play mobile game publishers like Zynga and Glu Mobile? Do they deserve a spot on your watch list?

Thanks to Bombfell for supporting The Motley Fool.  Get $25 off your first purchase at http://bombfell.com/fool

Donald Trump is likely to pull the US out of the Paris Climate Agreement – here’s what it means.

Thanks to Bombfell for supporting The Motley Fool.  Get $25 off your first purchase at http://bombfell.com/fool

Summer may not be the best time to own stocks historically, but embracing this old Wall Street adage is far from risk-less.

We look at major acquisition talks making headlines this week as American Eagle pursues its apparel rival Abercrombie & Fitch, and Kraft-Heinz eyes a mega-deal with Colgate-Palmolive.

Have you ever wondered what the Industry Focus cast is like in real life? This episode gives you a glimpse.

Game publishers Activision, Take-Two, and Electronic Arts have all soared so far in 2017. With all three up over 40% year-to-date, is it too late for investors to hop in and play?

OPEC extended its production cut for another 9 months, could this be a desperate move by a powerless cartel?

Extreme birth defects associated with a popular anti-anxiety medicine from the 1960's had a lasting impact on today's healthcare policy -- and the drug is still a major part of Celgene's cancer portfolio.

From McDonald’s “Experience of the Future” to Panera 2.0, the restaurant industry is investing heavily in technology as a means of reducing costs and improving the dining experience. Find out how different companies are approaching the automation and customer demands that loom over the horizon.

oin us for a primer on how the insurance industry works, how insurers make money, and how to evaluate insurance stocks for potential investment opportunities.

Twilio and Yelp are each down over 20% following earnings, are the drops signs of trouble or buying opportunities for investors?

Saudi Arabia and Russia desperately want oil back to its highs – but just how likely is it?

We dig into Valeant and Gilead Sciences' first quarter financials to see if shares are a bargain, or a bust.

Thanks to Slack for supporting The Motley Fool.  Learn more at slack.com.

A flurry of earnings reports from Macy’s, Nordstrom, and other department stores were greeted by bearish investors as shares declined as much as 20%. We drill down into the results before considering the longer term outlook for this industry.

Bitcoin might be the future. If you really want to understand it, you need to look at its past. Brian Patrick Eha's _How Money Got Free: Bitcoin and the Fight for the Future of Finance_ gives you the background you need to think about Bitcoin today.
Intro: Bitcoin. It's interesting, it's powerful, and it's confusing to most people. Luckily, Brian Patrick Eha has written a beautiful history and analysis of bitcoin. Join the Motley Fool's Gaby Lapera as she interviews Mr. Eha about his new book, _How Money Got Free: Bitcoin and the Fight for the Future of Finance_.

Snap's first quarter of financial results are out, and the numbers... weren't so great. We sort through the report, and dig into the details we didn't get in the company's original prospectus.

Thanks to Harry’s for supporting Industry Focus. Get your Free Trial Set – go to Harrys.com/fool

The oil & gas sector’s first quarter results are out, and the managements of these huge companies have made some interesting capital decisions.

With the $2.4 billion acquisition of Kate Spade, Coach hopes to reach millennial shoppers with a popular brand that it can eventually expand to new markets abroad. Meanwhile, Comcast and Charter team up to tackle the wireless industry.

Thanks to Harry’s for supporting the Motley Fool. To get your free trial set -- go to Harrys.com/fool

Motley Fool analyst Michael Douglass joins analyst Gaby Lapera to discuss key takeaways from this year's Berkshire Hathaway annual meeting.

Our favorite show of the quarter, Apple earnings! Plus what's up with WhatsApp and Facebook's other properties AND the final clues for puzzle week!

Oil has continued its drop in spite of OPEC’s promises to keep production low: What’s an investor to do?

Winners and losers can teach us valuable lessons about what's important -- and not important -- when it comes to investing.

Thanks to Slack for supporting The Motley Fool.  Learn more at www.slack.com

As the No. 2 name worldwide in sports apparel, Adidas deserves some extra attention from investors, especially as it continues to deliver industry-leading growth. With shares up nearly 200% in the past two years, here is what you need to know about the first major brand in sports.

What does the future of banking look like? That question is at the top of bankers' minds today. In this episode of Industry Focus: Financials, The Motley Fool's Gaby Lapera and John Maxfield discuss new technologies that are shaping the way banks serve customers.

Thanks to Slack for supporting The Motley Fool.  Learn more at www.slack.com

Twitter beat guidance and showed strong MAU growth in its most recent quarter, is it enough to start talking about a turnaround? Plus we hit Amazon's awesome earnings release.

Bad news for oil producers, great news for oil pipeline operators.

Missteps on repeal-and-replace mean business as usual for insurers, and first quarter results suggest that's a good thing. Also, Fresenius acquires Akorn, and Express Scripts' ongoing battle with Anthem "gets real".

Terrible fourth-quarter results, a slew of store closures, and bankruptcies have led to the perception that brick-and-mortar retail is experiencing a slow death, but opportunities abound for retailers willing to adapt and evolve.

The market looks at alternative asset managers and sees complexity, but some investors may see opportunity.

Answering a listener question, we talk about how hard it is to time the market, and why it's better for investors to ride out the waves and dollar-cost average.

Thanks to Warby Parker for supporting Motley Fool.  Order your FREE Home Try-On’s at http://www.warbyparker.com/fool

Fracking has been the oil industry buzzword for years, here’s what the process actually means.

After releasing its first quarter financials, J&J's stock fell over 3%. Is it a buy? In this episode, we dig into the quarter's highlights and low-lights to find out.

After seeing gambling revenue tumble 40% over two harrowing years, casino operators in Macau are breathing a sigh of relief as new, integrated resorts restore some growth to the region. With a massive new market also on the horizon, this will be an important industry to watch over the next several years.

Three of the nation's biggest banks reported first-quarter earnings last week. We discuss the results (and then some) in this week's episode of Industry Focus: Financials.

Thanks to Warby Parker for supporting Motley Fool. Order your FREE Home Try-On’s at http://www.warbyparker.com/fool

Russia loaned Venezuela’s state oil company, which owns CITCO, a lot of money – now they want to be paid back.

Deaths due to prescription opioids have quadrupled since 1999, but new drugs that reduce their use may help end the opioid epidemic.

In the past year, we have discussed the management shake-up at Viacom, as well as the $5.5 billion merger between Cabela’s and Bass Pro Shops. Both companies have hit roadblocks with their plans -- here is what you need to know.

With the April 18 tax filing deadline fast approaching, here are some things you need to know.

The average investor doesn't have a shot at buying shares of an IPO at issuance price... but that could be changing soon. ClickIPO's CEO Scott Coyle hops on the show to talk about the IPO market, and how his company is hoping to democratize access to IPO's and secondary issuances.

Oil prices are in limbo -- here's what the bulls have to say.

We all have cognitive biases, but if we're not careful, they can lead to bad investments. In this episode, we investigate the relationship between psychology and investing, and explain how you can outsmart your biases.

Thanks to Audible for supporting our podcast. Get a free audiobook with a free 30 day trial at audible.com/fool

We look at recent quotes from the management teams at Target and Dr. Pepper Snapple to determine whether their hopeful plans for the future should be accepted at face value by investors. In other news, Panera Bread hit a fresh all-time high Monday after news broke that the company is fielding buyout offers -- here are the companies likely to pursue a deal.

Over the past two decades, PNC Financial has evolved into one of the best-managed companies in the financial services sector. Listen in as The Motley Fool's Gaby Lapera and John Maxfield dissect what's behind its success.

Thanks to Audible for supporting our podcast. Get a free audiobook with a free 30 day trial at audible.com/fool

Snap got a bump early this week as a flurry of "Buy" notes came in from sell-side analysts. On this episode, we walk through the sell-side/buy-side dynamic and dig into the analyst reports.

In a classic case of whiplash, hedge funds are now turning sour on crude after bullish bets hit an all-time high just a few weeks ago – the Energy crew weighs in.

Thanks to Audible for supporting our podcast. Listen to Audible’s new original seires: Ponzi Supernove. Details at audible.com/ponzi. Audible and Amazon Prime members listen free.

A jam-packed month for news that includes a failed plan to replace Obamacare, a big cardiovascular study, a fast-approaching IPO, and a big advance in treating ovarian cancer has big implications on top healthcare stocks.

With billions of gamers and technology improving each year, video game companies are finding new ways to engage with customers. Here are some of the major takeaways for investors.

You asked for it! Motley Fool Options analyst JP Bennett hops on the show to do an introduction to options and answer some listener questions on the topic. 

Thanks to Audible for supporting our podcast. Listen to Audible’s new original series: Ponzi Supernova. Details at audible.com/ponzi. Audible and Amazon Prime members listen free.

Oil prices are up, but not anywhere near where their highs of 2014 – so why are producers upping production by 1 million barrel?

Veeva's President discusses the cloud solution company he co-founded, from its small beginnings in healthcare CRM to its latest Vault products and expansion outside of life sciences.

Asit Sharma joins the show to help answer questions from our Foolish listeners who want to know more about goodwill and the $300 billion food distribution industry.

Thanks to Audible for supporting our podcast. Listen to Audible’s new original series: Ponzi Supernova. Details at audible.com/ponzi. Audible and Amazon Prime members listen free.

Not every legendary investor is worth following, and not every way to get rich is as obvious as it may seem.

Sneaking in one more episode this week so we can bring listeners an interview we did with Comma.ai's George Hotz at SXSW. We talked with Hotz about the self-driving car tech his team is working on, some misconceptions about the segment, and what to watch in the coming years.

Thanks to Away for supporting Motley Fool. Go to awaytravel.com/fool and use the promo code fool to get $20 off your order!

New legislation passed last year that made it possible for the average investor to participate in early stage private investing rounds. How's it going so far? We sit down with Bill Clark of Microventures and Slava Rubin, founder of Indiegogo. 

Thanks to Away for supporting Motley Fool. Go to awaytravel.com/fool and use the promo code fool to get $20 off your order!

The Motley Fool’s Simon Erickson talks with Sean O’Reilly about what he learned at the SXSW Conference.

Thanks to Away for supporting Motley Fool. Go to awaytravel.com/fool and use the promo code fool to get $20 off your order!

Artificial intelligence and gene sequencing are changing how patients are treated. Analyst Simon Erickson shares some of the greatest opportunities and some of the biggest hurdles to adoption of the latest technology in healthcare.

Thanks to Away for supporting Motley Fool. Go to awaytravel.com/fool and use the promo code fool to get $20 off your order!

For the leading streaming service and global entertainment giant, product testing is always happening behind the scenes. Tune in to find out how both companies leverage various tools at their disposal to put forward the “perfect” customer experience.

Thanks to Away for supporting the Motley Fool. Go to awaytravel.com/fool and use the promo code “fool” to get $20 off your order!

Apparently Snap's IPO has a lot of people thinking about shorting stocks -- we answer a listener question and get into the nitty gritty risks of deciding to go short.

Here's why  Exelixis, Pacira Pharmaceuticals, Kite Pharma, Exact Sciences, and Portola Pharmaceuticals are up more than 50% in the first two months of 2017. 

Based on the latest network quality reports, most consumers will be happy with any of the Big Four wireless carriers, but one company continues to shake up the industry. We also provide an update on the struggle Bass Pro Shops is facing in its $4.5 deal with Cabela’s, before looking at the growing trend of delivery as a differentiator for restaurants.

The Oracle of Omaha just released his latest letter to the shareholders of Berkshire Hathaway. In this episode of Industry Focus, we talk about what he had to say. 

Snap's IPO went well, and the stock is flying high, but that hasn't changed our minds about the ephemeral messaging app/camera company.

Everyone is talking about autonomous vehicles these days, but how long until they are a reality?

How drugs are priced the way that they are, and how to determine if drug prices are fair. Also, what makes dollar cost averaging such a powerful investing strategy.

The cast looks at the latest earnings results for major department stores as a tough retail environment and major store closures dominate the headlines. They also reach into the mailbag to take a first look at VF Corporation.

A mortgage is many homeowners single biggest expense each month, so it pays to understand the costs -- especially for new home buyers and people searching for a lower rate to refinance their house. The Trump administration could affect mortgage costs throughout 2017. Join the Motley Fool’s Nathan Hamilton and Gaby Lapera to learn what you need to know about mortgages in 2017.

Digging through the company's earnings release, we break down what went wrong for Fitbit last year, and what management is doing to turn things around and find growth in 2017.

Energy storage is a hot topic these days, here’s who is currently leading the charge.

Carl Icahn's reportedly focusing his brand of investor activism on Bristol-Myers Squibb, but it's anyone's guess if he'll be able to convince the company to sell. Also, Celgene delivers a phase 3 win with blockbuster implications.

From price wars to automation, Fool.com contributor Daniel Kline offers his take on major trends currently driving innovation and growth at your favorite quick service restaurants.

Snap is one of the hottest potential IPO's of 2017. Now that we've had a chance to look at the numbers, should investors keep it on their watch list once shares start trading?

BP plc has released its 2017 Energy Outlook that extends to 2035. For long-term investors, BP's opinions may be both surprising and thought-provoking.

In this Valentine's Day edition, we explore cholesterol busters, heart surgery, and the latest in anticoagulants.

Dave was just a business school student when he and his friends decided to start an eyewear company that would eventually revamp the entire industry. Now serving as co-CEO of Warby Parker, he shares his story and offers some insight into the state of retail.

 Thanks to Audible for supporting our podcast. Get a free audiobook with a free 30-day trial at audible.com/fool.

The Dodd-Frank Act dramatically transformed the bank industry when it was passed in 2010. But fast forward to today and President Trump is promising to make it a thing of the past. On this week's episode of Industry Focus, Gaby and John provide a comprehensive look at not only the history and purpose of Dodd-Frank, but also how it might be reformed.

We explain why Facebook and Shopify are two tech stocks we really like, and answer Gaby's questions about the companies.

Thanks to Audible for supporting our podcast. Get a free audiobook with a free 30 day trial at audible.com/fool.

There are many green stocks in the marketplace, here are two of the top plays today.

Thanks to Thumbtack for supporting Motley Fool. Hire local, skilled pros for just about anything at thumbtack.com today.

 These companies are disrupting their respective industries, and each has catalysts that could reward investors in the future. Is one a better stock to buy than the other?

Thanks to Audible for supporting our podcast. Get a free audiobook with a free 30 day trial at audible.com/fool.

We welcome financials analyst Gaby Lapera to the show to share some of our favorite stocks in the consumer and retail sector. In this case, leading companies in their respective industries can still make for a David and Goliath story. 

Thanks to Thumbtack for supporting Motley Fool. Hire local, skilled pros for just about anything at thumbtack.com today.

Listen as two great stocks in the financials sector face off against each other.

Apple's recent quarterly check-ins have been fairly ho-hum, but not this time! The Mac maker is back to growth after an impressive quarter, we explain what segments pushed the company over the top, and what investors can expect next quarter.

Forget that power plant off in the distance, these places have wind mills present on the horizon.

Competitors make headway against Teva Pharmaceutical's top-seller, and Biogen's hemophilia drugs become Bioverativ. Here's what you should know.

Will Airbnb launch its IPO in 2017? Is Macau officially on track for a recovery? Will Japan eventually become the new casino capital of the world? Fool.com contributor Seth McNew shares his insights after traveling through the regio

Use these tips to get out of debt and make the most of your credit.

It's earnings season, so we're breaking down quarterly results from two Fool favorites, Alphabet and Paypal. We hit the headline numbers, key metrics, and dig through management's comments to catch all the info investors need to know.

Aircraft production is basically a duopoloy with just two major players – here’s what investors need to know.

From a big-time patent settlement between Merck & Co. and Bristol-Myers Squibb, to Johnson & Johnson's earnings,  to Aetna and Humana's $37 billion merger bust, we dive into the details behind this week's biggest healthcare stories.

Take two leading companies in the eyewear industry, combine them, and what do you get? In this case, say hello to EssilorLuxottica, a massive enterprise that will boast 140,000 employees,  $16 billion of annual revenue, and a global scale that overshadows its closest competitors by a wide margin.

Michael Douglass returns to talk about his framework for analyzing companies and we run Facebook through his wringer. Is it a buy?

The 2017 Detroit International Auto Show just ended and there were big takeaways for consumers and investors alike.

A system that could revolutionize gene research and a first-in-class cancer therapy could be two of healthcare's biggest advances this year. Plus, United Healthcare's earnings review, and a preview of Johnson & Johnson's earnings.

Women have been the driving force behind the rise of activewear in the apparel industry. In this episode, we discuss the long-term trends that will continue to fuel this segment and the companies poised to benefit from the nearly $80 billion athleisure market.

We run through a couple different tips to make your resolutions easier to hit in 2017 and talk about why we're focusing on doing more stock research, checking out credit cards, and changing our online passwords.

 U.S. oil production has bottomed out and is on the upswing, here’s what you need to know to position your portfolio the right way.

Promo: How to build a profit-friendly stock watch list. Plus, Trump’s tough talk on drug costs and why it’s so important to pay off your credit card debt ASAP.

With just under 51 weeks left to go in 2017, many people are just beginning to hit their stride, working hard on their resolutions. In this episode, the cast discusses their own goals for the new year and why it can be so difficult to keep up with resolutions for the entire year.

Millions of people will make New Years Resolutions this year. Some will adopt their resolutions completely, while others are forgotten after just a few short weeks. In this edition of Industry Focus: Financials, join The Motley Fool's Gaby Lapera and Jordan Wathen as they discuss their financial New Year's Resolutions, and check the scoreboard on 12 predictions Jordan made for BDCs in 2015. 

We phone up our boots on the ground at the Consumer Electronics Show to see what big tech trends are being showcased this week in Las Vegas.

Drilling activity is already increasing in the U.S. – here’s what investors need to know.

Beaten-up biotech has some work to do to restore investor confidence. Here's how Gilead Sciences, Valeant Pharmaceuticals, and the entire industry can get back on track in 2017.

Grab your popcorn and have a seat as we look back at the record-setting slate of movie releases from last year, the leading entertainment companies behind them, and what film-loving investors can expect in 2017.